Risk factors for the development of bacterial infections in patients with multiple myeloma treated with two different vincristine-adriamycin-dexamethasone schedules

Haematologica

Volumn 88, Issue 9, 2003, Pages 1022-1028

  Cesana, Clara ^a,b   Nosari, Anna Maria ^a   Klersy, Catherine ^c   Miqueleiz, Sara ^a   Rossi, Valentina ^a   Ferrando, Paola ^d   Valentini, Marina ^a   Barbarano, Luciana ^a   Morra, Enrica ^a,e  

^a OSPEDALE NIGUARDA CA GRANDA   (Italy)

^b Citta di Sesto San Giovanni Hospital   (Italy)

^c FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^d A MANZONI HOSPITAL   (Italy)

^e FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

Bacterial infection; Multiple myeloma; VAD

Indexed keywords

ANTIBIOTIC AGENT; DEXAMETHASONE; DOXORUBICIN; IMMUNOGLOBULIN; VINCRISTINE;

ADULT; AGED; ANTIBIOTIC PROPHYLAXIS; ARTICLE; BACTERIAL INFECTION; DISEASE ASSOCIATION; DRUG EFFICACY; FEMALE; HOSPITAL INFECTION; HOSPITALIZATION; HUMAN; HYPOGAMMAGLOBULINEMIA; INCIDENCE; INFECTION RISK; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; NEUTROPENIA; RETROSPECTIVE STUDY; RISK FACTOR;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BACTERIAL INFECTIONS; DEXAMETHASONE; DOXORUBICIN; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FEMALE; HUMANS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RETROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; VINCRISTINE;

EID: 0141702160     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Jacobson DR, Zolla-Pazner S. Immunosuppression and infection in multiple myeloma. Semin Oncol 1986;13:282-90.
2. Hargreaves RM, Lea JR, Griffiths H, Faux JA, Holt JM, Reid C, et al. Immunological factors and risk of infection in plateau phase myeloma. J Clin Pathol 1995;48:260-6.
3. Perri RT, Hebbel RP, Oken MM. Influence of treatment and response status on infection risk in multiple myeloma. Am J Med 1981;71:935-40.
4. Savage DG, Lindenbaum J, Garret TJ. Biphasic pattern of bacterial infection in multiple myeloma. Ann Intern Med 1982;96:47-50.
5. Barlogie B, Smith L, Alexanian R. Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med 1984;310:1353-6.
6. Egerer G, Hegenbart U, Salwender H, Haas R, Hahn U, Schmier JW, et al. Outpatient treatment of multiple myeloma with a combination of vincristine, adriamycin and dexamethasone. Support Care Cancer 2001;9:380-5.
7. Lokhorst HM, Meuwissen OJAT, Bast EJEG, Dekker AW. VAD chemotherapy for refractory multiple myeloma. Br J Haematol 1989;71:25-30.
8. Samson D, Gaminara E, Newland A, Van de Pette J, Kearney J, McCarthy D, et al. Infusion of vincristine and doxorubicin with oral dexamethasone as first-line therapy for multiple myeloma. Lancet 1989;989:882-5.
9. Segeren CM, Sonneveld P, van der Holt B, Baars JVV, Biesma DH, Cornellissen JJ, et al. Vincristine, doxorubicin and dexamethasone (VAD) administered as rapid intravenous infusion for first-line treatment in untreated multiple myeloma. Br J Haematol 1999;105:127-30.
10. Barlogie B, Jagannath S, Desikan KR, Mattox S, Vesole D, Siegel D, et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 1999;93:58-65.
11. Tribalto M, Amadori S, Cudillo L, Caravita T, Del Poeta G, Meloni G, et al. Autologous peripheral blood stem cell transplantation as first line treatment of multiple myeloma. An Italian multicenter study. Haematologica 2000;85:52-8.
12. alumbo A, Triolo S, Baldini L, Callea V, Capaldi A, De Stefano V. Dose-intensive melphalan with stem cell support (CM regimen) is effective and well tolerated in elderly myeloma patients. Haematologica 2000;88:508-13.
13. Oken MM, Pomeroy C, Weisdorf D. Prophylactic antibiotics for the prevention of early infection in multiple myeloma. Am J Med 1996;100:624-8.
14. Rubin RH, Ikonen T, Gummert JF, Morris RE. The therapeutic prescription for the organ transplant recipient: the linkage of immunosuppression and antimicrobial strategies. Transpl Infect Dis 1999;1:29-39.
15. Chapel HM, Lee M, Hargreaves R, Pamphilon DH, Prentice AG. Randomised trial of intravenous immunoglobulin as prophylaxis against infection in plateau-phase multiple myeloma. Lancet 1994;343:1059-63.
16. Friedenberg WR, Kyle RA, Knospe WH, Bennett JM, Tsiatis AA, Oken MM. High-dose dexamethasone for refractory or relapsing multiple myeloma. Am J Hematol 1991;36:171-5.
17. Sarnak MJ, Jaber BL. Pulmonary infectious mortality among patients with end-stage renal disease. Chest 2001;120:1883-7.
18. Engelich G, Wright DG, Hartshorn KL. Acquired disorders of phagocyte function complicating medical and surgical illness. Clin Infect Dis 2001;33:2040-8.